ArticleAmerican journal of translational research2026
Effect of intravenous infusion of remimazolam versus propofol on intraoperative neurophysiological monitoring stability and postoperative neurological function in patients undergoing spinal surgery.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIntraoperative neurophysiological monitoring (IONM) plays a critical role in spinal surgery by reducing the risk of nerve injury; however, its quality can be significantly influenced by anesthetic agents. This study aimed to compare the effects of remimazolam and propofol on IONM performance and postoperative recovery.
methodsThis retrospective analysis included patients who underwent prone-position spinal surgery with IONM between January 2021 and June 2025. Patients were divided into either a remimazolam group or a propofol group according to the primary sedative administered. The outcomes assessed included IONM parameters [somatosensory evoked potentials (SEP)/motor evoked potentials (MEP) amplitude/latency] after intubation (T1) and at 30 min (T3) and 50 min (T4) following recovery from neuromuscular blockade. Additional outcomes included hemodynamics, remifentanil consumption, recovery time, and cognitive function scores.
resultsA total of 204 patients included in the analysis (Remimazolam group: 101 cases, Propofol group: 103 cases). Compared to the propofol group, the remimazolam group demonstrated significantly improved IONM signals, higher SEP amplitude at T4 (2.16 vs. 1.97 μV, P<0.001), and higher MEP amplitude at T4 (1680.73 vs. 1500.64 μV, P<0.001). The incidence of hypotension (6.93% vs. 19.42%, P=0.009) and bradycardia (5.94% vs. 14.56%, P=0.043) were significantly lower, while remifentanil consumption was significantly higher (2005.64 vs. 1425.44 ug, P<0.001) in the remimazolam group. In addition, patients in the remimazolam group exhibited shorter recovery times (awakening time: 18.91 vs. 24.25 min, P<0.001) and better cognitive function (MoCA score on postoperative Day 3: 24.41 vs. 23.54, P<0.001).
conclusionsRemimazolam provides superior IONM conditions, a lower incidence of intraoperative hypotension and bradycardia, and faster postoperative recovery compared to propofol in patients undergoing spinal surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.